Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece. - Wikidata - wikimedia - TriplyDB

Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece.

Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece.

http://www.wikidata.org/entity/Q37616932

about

Chinese Herbal Medicines Might Improve the Long-Term Clinical Outcomes in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: Results of a Decision-Analytic Markov Model.Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review.Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice.Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan.Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece.

P2860

Q36163383-8A7A01BA-1C51-48F3-9DC6-F899D0E0ED6A Q38386998-4C5C43AB-347E-4074-B377-EEDE8A2D988B Q38713953-9A6BCC7F-E380-4D77-898D-56FBAD36CA5B Q39096950-366A4527-5113-4A30-B7A9-B3E131B0E547 Q39187952-CFE8AA00-C964-436C-B1FD-587DB801CE99 Q39823839-87269AF0-1100-4A98-B281-A72E1680C7A5 Q40162266-DA26E7C1-8A71-4047-94B2-6A2E3ADEC9D0

P2860

Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece.

http://www.wikidata.org/entity/Q37616932

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 February 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Economic evaluation of rivarox ...... atrial fibrillation in Greece.

@en

Economic evaluation of rivarox ...... atrial fibrillation in Greece.

@nl

type

label

Economic evaluation of rivarox ...... atrial fibrillation in Greece.

@en

Economic evaluation of rivarox ...... atrial fibrillation in Greece.

@nl

prefLabel

Economic evaluation of rivarox ...... atrial fibrillation in Greece.

@en

Economic evaluation of rivarox ...... atrial fibrillation in Greece.

@nl

P1433

Q37616932-39118CEA-87EF-494A-9B99-2E1C4DC9CB14

P1476

Q37616932-37658646-241D-47F1-A572-065C3C97A04F

P2093

Q37616932-0D488434-740B-46A7-BB88-A4D9C4A0C200

Q37616932-23B0F070-9258-4827-829B-58F6C41245CD

Q37616932-2EC7B1BF-E92F-4283-A5E5-48FB01758394

Q37616932-76314DA2-4B32-43C5-8D56-4FC9840495F5

P2860

Q37616932-0817BFD5-A844-4FC0-ACCA-9C4B5225BE59

Q37616932-083BCF42-A3EC-492B-ACD1-8FADA5F79264

Q37616932-0EAAB548-7D14-465C-80E8-55F96646FAA5

Q37616932-1AD9463B-AFED-4D49-A66E-03BB131EFFC8

Q37616932-207E519E-9FB6-402C-BD98-D234C116C1D2

Q37616932-240B7688-EB84-41B0-84FC-D35DA21A2899

Q37616932-281332BD-2B52-4127-8518-4E58C635672B

Q37616932-2BE7859E-175A-4DD7-8F77-64B5BFDEC887

Q37616932-39A9D9C6-6B25-449E-83DA-3148D6F6B713

Q37616932-44865496-74E5-433A-8754-C77A695FD8F3

P2888

Q37616932-AC02F7DD-3BC6-4579-A75E-771F8CF40B29

P304

Q37616932-1591C5DC-83EE-4901-8B52-C20B4C2B5784

P31

Q37616932-6E0253BA-CEF3-4670-B7FD-1C245467E46C

P356

Q37616932-FEB3DFE6-4B86-4FE6-8261-8FBBD96CEDD7

P433

Q37616932-2D084CC4-2C30-4F76-B37C-AD63966ADB66

P478

Q37616932-D921B734-D135-49E6-B0D7-1A486A80E401

P577

Q37616932-184C1CD8-B4F3-4E04-A8A4-5C5C14892403

P5875

Q37616932-2F683799-A6B9-42DA-B84D-C9A5DDB91E41

P6179

Q37616932-5C61CFCF-DB63-44C5-BE8A-51CAAB38B9F8

P698

Q37616932-C470A34F-77CA-4BF8-AA3D-8173F947B77D

P921

Q37616932-2270D2B2-B77C-4C91-A0CF-1CF06E1A6A3F

P932

Q37616932-7FEE5880-2EDE-4F06-9057-F650B9521E1D

P356

P1433

Cost Effectiveness and Resource Allocation

P1476

Economic evaluation of rivarox ...... atrial fibrillation in Greece.

@en

P2093

George Andrikopoulos

http://www.w3.org/2001/XMLSchema#string

Georgia Kourlaba

http://www.w3.org/2001/XMLSchema#string

Nikos Maniadakis

http://www.w3.org/2001/XMLSchema#string

Panos Vardas

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US

Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol

Validation of Clinical Classification Schemes for Predicting Stroke

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis.

Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis.

Quality of life in patients with atrial fibrillation: a systematic review.

Outcome parameters for trials in atrial fibrillation: executive summary.

Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.

P2888

P304

5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1478-7547-12-5

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260151438

http://www.w3.org/2001/XMLSchema#string

P6179

1048972973

http://www.w3.org/2001/XMLSchema#string

P698

24512351

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation

P932

3942277

http://www.w3.org/2001/XMLSchema#string